布地奈德治疗效果

Therapeutic effect of budesonide: In the clinical trial, 85 patients with bronchial asthma who received treatment were selected and divided into an experimental group of 43 cases and a control group of 42 cases using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with Budesonide. After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant (P<0.05). No serious adverse reactions occurred in the two groups of patients, and the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Budesonide has significant efficacy and high safety when used in bronchial asthma. It is a good choice for patients.

Budesonide was first developed and marketed by AstraZeneca Pharmaceutical Company in 1981. It was approved for marketing by the US FDA in August 2000, and my country approved its import and marketing in November 2001. For the treatment of patients with bronchial asthma and mild to moderate colonic Crohn's disease.

Budesonide is a glucocorticoid with highly effective local anti-inflammatory effects. It can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune responses and reduce antibody synthesis, thereby reducing the release and activity of allergic active mediators such as histamine. It can also reduce the enzymatic process triggered when antigens and antibodies are combined, inhibit the synthesis and release of bronchoconstrictive substances and reduce the contractile response of smooth muscles. Acute, subacute and long-term toxicity studies have found that the systemic effects of budesonide, such as weight loss, lymphoid tissue and adrenal cortex atrophy, are weaker than or equivalent to other glucocorticoids. After systematic evaluation in six different experimental tests, Budesonide has no mutagenic or carcinogenic effects.